Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB plus ) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C

Dziadziuszko, R.Peters, S.Gadgeel, S. M.Mathisen, M. S.Shagan, S. M.Felip, E.Morabito, A.Cheema, P.Cobo Dols, M.Andric, Z.Barrios, C. H.Yamaguchi, M.Dansin, E.Danchaivijitr, P.Johnson, M.Novello, S.Gandara, D. R.Schleifman, E.Wang, J.Mok, T. S. K.2025-01-072025-01-072021-09-210923-7534https://hdl.handle.net/10668/26996enAtezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB plus ) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort Cconference outputopen access10.1016/j.annonc.2021.08.18831569-8041https://doi.org/10.1016/j.annonc.2021.08.1883700527702210